Anti-inflammatory drug for narrowing arteries in the brain
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether a drug that lowers inflammation can reduce the risk of another stroke in people with narrowing of a brain artery. The treatment is given after a mild stroke or mini-stroke.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You had a mild stroke or a mini-stroke in the last 3 days.
- Tests show that one of the main arteries in your brain is narrowed by 50% to 99%.
- You have not had clot-busting medicine or a procedure to remove a clot in the last 24 hours.
- You are willing to attend follow-up visits as needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks if adding an interleukin-6 receptor inhibitor (a drug that reduces inflammation) to standard emergency clot removal can improve recovery for people with a severe stroke affecting the back part of the brain (posterior circulation). It is for patients who need urgent treatment within 24 hours of symptom onset.
This study looks at how your immune system reacts to stroke treatments like clot-busting drugs or mechanical clot removal. The goal is to see if immune markers can predict recovery, which could help tailor future stroke care.
This Phase 1/2 trial tests infliximab, a medicine that calms inflammation, for dolichoectactic aneurysms in the vertebral/basilar brain blood vessels that usually cannot be treated with standard surgery or procedures. The goal is to see if it can improve safety and how the aneurysm behaves over time.
This trial studies whether giving an anti-inflammatory drug called tocilizumab after emergency clot removal improves recovery from a severe stroke caused by a blocked artery in the brain.
This trial tests a combination of blood thinners (anticoagulation) and a drug called tocilizumab, which targets inflammation, to treat acute cerebral venous thrombosis (a blood clot in a vein in the brain). It aims to see if this combined treatment improves recovery and reduces complications compared to blood thinners alone.
This trial tests if a drug called tocilizumab (TYENNE) can reduce the risk of delayed strokes after a bleeding stroke from a ruptured aneurysm. It is for adults who had a specific type of brain bleed and need a drain to remove fluid.
Hear when a new Brain Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.